ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
The current price of ICCC.BOATS is $5.65 USD — it has decreased by -6.77% in the past 24 hours. Watch Immucell stock price performance more closely on the chart.
What is Immucell stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immucell stocks are traded under the ticker ICCC.BOATS.
What is Immucell market cap?▼
Today Immucell has the market capitalization of 51.11M
When is the next Immucell earnings date?▼
Immucell is going to release the next earnings report on May 20, 2026.
What is Immucell revenue for the last year?▼
Immucell revenue for the last year amounts to 52.99M USD.
What is Immucell net income for the last year?▼
ICCC.BOATS net income for the last year is -4.31M USD.